• Xencor (XNCR) Phase 1 Results of XmAb7195 for Asthma and Allergic Disease

       (0 reviews)

    Biotech_Forecast
    Clinical and Regulatory
    Event Type: Phase 1 Results
    Timing: H1 2017
    Designation(s): None

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Respiratory
    Indication: Asthma and Allergic Disease
    Lead Indication?: No
    Treatment Name: XmAb7195

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: Xencor
    Stock Symbol: XNCR
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://investors.xencor.com/releasedetail.cfm?ReleaseID=977312
    Partnership: No

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement

     

    Quote

    XmAb7195 is a first-in-class monoclonal antibody that targets IgE with its variable domain and uses Xencor's XmAb Immune Inhibitor Fc domain to target FcgRIIb, resulting in three distinct mechanisms of action for reducing IgE levels. In May 2016, Xencor presented data from a Phase 1a trial at the American Thoracic Society Annual Meeting.

    Today, Xencor will discuss the recently presented data from the Phase 1a study of XmAb7195 showing that XmAb7195 was generally well tolerated and induced rapid and extensive depletion of serum IgE at all doses tested, including in high IgE subjects. A Phase 1 multiple ascending dose study with subcutaneous administration of XmAb7186 is expected to begin this year with initial data expected in the first half of 2017.

     

     


      Report Event


    User Feedback

    There are no reviews to display.